Show simple item record

dc.contributor.authorHampel, Harald
dc.contributor.authorShen, Yong
dc.contributor.authorWalsh, Dominic M
dc.contributor.authorAisen, Paul
dc.contributor.authorShaw, Les M
dc.contributor.authorZetterberg, Henrik
dc.contributor.authorTrojanowski, John Q
dc.contributor.authorBlennow, Kaj
dc.date.accessioned2010-07-15T12:40:48Z
dc.date.available2010-07-15T12:40:48Z
dc.date.issued2010-06
dc.identifier.citationBiological markers of amyloid beta-related mechanisms in Alzheimer's disease. 2010, 223 (2):334-46 Exp. Neurol.en
dc.identifier.issn1090-2430
dc.identifier.pmid19815015
dc.identifier.doi10.1016/j.expneurol.2009.09.024
dc.identifier.urihttp://hdl.handle.net/10147/107733
dc.description.abstractRecent research progress has given detailed knowledge on the molecular pathogenesis of Alzheimer's disease (AD), which has been translated into an intense, ongoing development of disease-modifying treatments. Most new drug candidates are targeted on inhibiting amyloid beta (Abeta) production and aggregation. In drug development, it is important to co-develop biomarkers for Abeta-related mechanisms to enable early diagnosis and patient stratification in clinical trials, and to serve as tools to identify and monitor the biochemical effect of the drug directly in patients. Biomarkers are also requested by regulatory authorities to serve as safety measurements. Molecular aberrations in the AD brain are reflected in the cerebrospinal fluid (CSF). Core CSF biomarkers include Abeta isoforms (Abeta40/Abeta42), soluble APP isoforms, Abeta oligomers and beta-site APP-cleaving enzyme 1 (BACE1). This article reviews recent research advances on core candidate CSF and plasma Abeta-related biomarkers, and gives a conceptual review on how to implement biomarkers in clinical trials in AD.
dc.language.isoenen
dc.subject.meshAlzheimer Disease
dc.subject.meshAmyloid beta-Protein
dc.subject.meshBiological Markers
dc.subject.meshBrain
dc.subject.meshClinical Trials as Topic
dc.subject.meshHumans
dc.titleBiological markers of amyloid beta-related mechanisms in Alzheimer's disease.en
dc.contributor.departmentDiscipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience (TCIN), Laboratory of Neuroimaging and Biomarker Research, Trinity College Dublin, Trinity Centre for Health Sciences, The Adelaide and Meath Hospital Incorporating The National Children's Hospital (AMiNCH), Dublin, Ireland; Department of Psychiatry, Alzheimer Memorial Center, Ludwig Maximilian University, Munich, Germany.en
dc.identifier.journalExperimental neurologyen
refterms.dateFOA2018-08-22T08:33:47Z
html.description.abstractRecent research progress has given detailed knowledge on the molecular pathogenesis of Alzheimer's disease (AD), which has been translated into an intense, ongoing development of disease-modifying treatments. Most new drug candidates are targeted on inhibiting amyloid beta (Abeta) production and aggregation. In drug development, it is important to co-develop biomarkers for Abeta-related mechanisms to enable early diagnosis and patient stratification in clinical trials, and to serve as tools to identify and monitor the biochemical effect of the drug directly in patients. Biomarkers are also requested by regulatory authorities to serve as safety measurements. Molecular aberrations in the AD brain are reflected in the cerebrospinal fluid (CSF). Core CSF biomarkers include Abeta isoforms (Abeta40/Abeta42), soluble APP isoforms, Abeta oligomers and beta-site APP-cleaving enzyme 1 (BACE1). This article reviews recent research advances on core candidate CSF and plasma Abeta-related biomarkers, and gives a conceptual review on how to implement biomarkers in clinical trials in AD.


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
19815015.pdf
Size:
1.239Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record